TRANSCODE THERAPEUTICS, INC.

BOSTON, MA · Biotech · Public

MN-anti-miR10b (TTX-MC138), an antagomir therapeutic targeting microRNA-10b conjugated to a proprietary tumor-targeting delivery platform for metastatic cancer treatment

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · transcodetherapeutics.com

Sector: Biotech
Headquarters: BOSTON, MA
Latest Form D: $8M, Dec 2024
Total capital: $12.3M

Federal grants: $4.3M; 5 awards · 2021–2025; Rank in peer group#205 of 514
Private capital raised: $8M; 1 Form D · last Dec 2024; 22 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 0; 6 pending

Capital timeline

Latest events

Jun 2025Federal grantHealth and Human S · Phase II · Phase I Clinical Testing of a First-in-Class Therapy against Metastatic Cancer$989K
Dec 2024Private capital raisedForm D · SEC · 1st filing$8M
Sep 2024Federal grantHealth and Human S · Phase II · Phase I Clinical Testing of a First-in-Class Therapy against Metastatic Cancer$1M
Apr 2023Federal grantHealth and Human S · Phase II · Clinical Development of First-in-Class Therapy for Metastatic Breast Cancer$871K
May 2022Federal grantHealth and Human S · Phase II · Clinical Development of First-in-Class Therapy for Metastatic Breast Cancer$1.1M
Apr 2021Federal grantHealth and Human S · Phase II · Clinical Development of First-in-Class Therapy for Metastatic Breast Cancer$309K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

44months

from TRANSCODE THERAPEUTICS, INC.’s first federal award to its first private round.

First federal award · Apr 2021: Health and Human S · $309K
First Form D · Dec 2024: $8M · 1st Form D
Awards before first raise: 4 awards

An association in public records, not a cause or a prediction.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grants#205 · top 40%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings

Erik A. MantingDirectorNamed in SEC Form D filings
Magda A. MarquetDirectorNamed in SEC Form D filings
Philippe A. CalaisDirectorNamed in SEC Form D filings
Thomas A. FitzgeraldExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 6

May 23, 2024PendingTemplate Directed Immunomodulation For Cancer TherapyUSPTOApplication 18270361
Feb 8, 2024PendingNanoparticles And Template Directed Rig-i Agonist Precursor Compositions And Uses Thereof For Cancer TherapyUSPTOApplication 18215550
PendingNanoparticles And Template Directed Rig-i Agonist Precursor Compositions And Uses Thereof For Cancer TherapyUSPTOApplication PCTUS2023026460

Show all 6 patent records

Template Directed Immunomodulation For Cancer TherapyMay 23, 2024 · Application 18270361Pending
Nanoparticles And Template Directed Rig-i Agonist Precursor Compositions And Uses Thereof For Cancer TherapyFeb 8, 2024 · Application 18215550Pending
Nanoparticles And Template Directed Rig-i Agonist Precursor Compositions And Uses Thereof For Cancer TherapyApplication PCTUS2023026460Pending
Radiolabeled Nanoparticles And Template Directed Immunomodulation For Cancer TherapyApplication 63356449Pending
Template Directed Immunomodulation For Cancer TherapyApplication PCTUS2021065580Pending
Compositions And Methods For Eliciting An Immune Response To Specific RnasApplication 63132315Pending

Rgenta Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
REVEL PHARMACEUTICALS INC.Similar federal contract value in Biotech · null in contracts
ADRX, INC.Similar federal contract value in Biotech · null in contracts
1910 GENETICS INC.Similar federal contract value in Biotech · null in contracts
ELYSIUM THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
BLACKFYNN, INC.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.